Duloxetine in the Treatment of Stress Urinary Incontinence.

Phase 3CompletedNCT00191087

Eli Lilly and Company458 enrolled

Overview

The purpose of this study is to monitor the long term safety of duloxetine in the treatment of stress urinary incontinence.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

458

Conditions

Urinary Incontinence, Stress

Interventions

DuloxetineDRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women with predominant stress urinary incontinence. * 7 or more incontinence episodes per week. Exclusion Criteria: * Use of monoamine inhibitors.

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.

London, England, United Kingdom

Outcomes

Primary Outcomes

To generate long-term safety data for duloxetine in the treatment of women with stress urinary incontinence

Secondary Outcomes

To collect data to demonstrate the maintenance of effect of duloxetine as measured by patient Global Impression of Improvement (PGI-I) questionnaire.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.